Patients with chronic renal disease have to be vaccinated as soon as dialysis is forestalled and this could improve seroconversion rate of hepatitis B vaccination.

In this study, the investigators aimed to compare seroconversion rates and immune response rates using four doses of 40 μg and three doses of 20 μg of Euvax B recombinant hepatitis B surface antigen (HBsAg) vaccine given to predialysis CKD patients.

In an open, randomized clinical trial, the investigators compared seroconversion rates in 51 predialysis patients with mild and moderate chronic renal failure using either 40 μg 4 doses or 20 μg 3 doses of Euvax B recombinant hepatitis B vaccine administered at 0, 1, 2, 6 and 0, 1, 6 months respectively.

Inclusion Criteria:

• predialysis patients,
• > 18 years with mild and moderate chronic renal failure,
• serum creatinine between 1.5-6 mg/dl

Exclusion Criteria:

• patients with severe renal failure,
• serum creatinine > 6 mg/dl,
• requiring dialysis or expected to require dialysis within 1 year,
• receiving immunosuppressive treatment,
• known lymphoproliferative disorder.